Trial · NCT02800148
Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face
NCT02800148, Phase 3, Completed, Padagis LLC; results first posted 2020-12-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face. Trials, record NCT02800148. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02800148
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face
- NCT number
- NCT02800148
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 667 participants, actual
- Lead sponsor
- Padagis LLC
- Conditions
- Rosacea
- Interventions
- Azelaic acid foam, Azelaic acid foam, Azelaic acid foam - Placebo
- First posted
- 2016-06-15
- Last updated
- 2021-11-08
- Results first posted
- 2020-12-09
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Change (Reduction) of Lesion Count From Day 1 | Day 84 |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change (Reduction) of Lesion Count From Day 1 | Day 84 | percentage of lesion reduction | MEAN |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change (Reduction) of Lesion Count From Day 1 | Azelaic Acid Foam | 61.14 | Standard Deviation 33.623 | percentage of lesion reduction | |
| Percent Change (Reduction) of Lesion Count From Day 1 | Finacea Foam | 57.27 | Standard Deviation 34.513 | percentage of lesion reduction | |
| Percent Change (Reduction) of Lesion Count From Day 1 | Placebo Foam | 49.43 | Standard Deviation 44.437 | percentage of lesion reduction |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Azelaic Acid Foam | 224 | |
| Overall Study | STARTED | Finacea Foam | 224 | |
| Overall Study | STARTED | Placebo Foam | 219 | |
| Overall Study | COMPLETED | Azelaic Acid Foam | 199 | |
| Overall Study | COMPLETED | Finacea Foam | 204 | |
| Overall Study | COMPLETED | Placebo Foam | 194 | |
| Overall Study | NOT COMPLETED | Azelaic Acid Foam | 25 | |
| Overall Study | NOT COMPLETED | Finacea Foam | 20 | |
| Overall Study | NOT COMPLETED | Placebo Foam | 25 |
Source ClinicalTrials.gov
Adverse events12
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Esophageal Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Azelaic Acid Foam | 1 | 224 | |
| serious | Esophageal Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Finacea Foam | 0 | 224 | |
| serious | Esophageal Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo Foam | 0 | 219 | |
| serious | Aseptic Meningitis | Infections and infestations | Azelaic Acid Foam | 0 | 224 | |
| serious | Aseptic Meningitis | Infections and infestations | Finacea Foam | 0 | 224 | |
| serious | Aseptic Meningitis | Infections and infestations | Placebo Foam | 1 | 219 | |
| serious | Major Depression | Psychiatric disorders | Azelaic Acid Foam | 0 | 224 | |
| serious | Major Depression | Psychiatric disorders | Finacea Foam | 0 | 224 | |
| serious | Major Depression | Psychiatric disorders | Placebo Foam | 1 | 219 | |
| serious | Suicidal ideation | Psychiatric disorders | Azelaic Acid Foam | 0 | 224 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Azelaic Acid Foam | 0 | 224 |
| Total, all-cause mortality | Finacea Foam | 0 | 224 |
| Total, all-cause mortality | Placebo Foam | 0 | 219 |
| Total, other adverse events | Azelaic Acid Foam | 0 | 224 |
| Total, other adverse events | Finacea Foam | 0 | 224 |
| Total, other adverse events | Placebo Foam | 0 | 219 |
| Total, serious adverse events | Azelaic Acid Foam | 1 | 224 |
| Total, serious adverse events | Finacea Foam | 0 | 224 |
| Total, serious adverse events | Placebo Foam | 2 | 219 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02800148
GET https://conductscience.org/api/trials/v1/NCT02800148/registered